Trials / Recruiting
RecruitingNCT06136364
CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study
Open-label, Dose-escalation Phase 1 Clinical Study of SENL101 Autologous T Cell Injection in the Treatment of Adult Patients With Relapsed or Refractory T-LBL/ALL
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (estimated)
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the tolerability and safety of SENL101 in patients with relapsed or refractory T-LBL/ALL.
Detailed description
Main research purposes: To evaluate the tolerability and safety of SENL101 in patients with relapsed or refractory T-LBL/ALL. Secondary research purposes: To preliminarily evaluate the efficacy, pharmacokinetics and pharmacodynamics of SENL101 in the treatment of patients with relapsed or refractory T-LBL/ALL. Exploratory research purpose： 1. To explore the immunogenicity of SENL101； 2. T cell NK cell recovery time after treatment；
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CAR-T | CAR-T immunotherapy targeting CD7+ |
Timeline
- Start date
- 2023-08-15
- Primary completion
- 2024-08-15
- Completion
- 2038-08-14
- First posted
- 2023-11-18
- Last updated
- 2023-11-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06136364. Inclusion in this directory is not an endorsement.